The story began to unfold in recent years when large-scale genetic studies pointed an unexpected finger at ITSN1. One analysis combining the deCODE, UK Biobank, and Accelerating Medicines Partnership Parkinson’s Disease datasets found that heterozygous loss-of-function variants in the gene, meaning changes that cripple one of the two inherited copies, confer a substantially elevated risk of Parkinson’s disease. A second study described five patients from three families carrying distinct frameshift variants in ITSN1, documenting their clinical pictures in detail. A third effort, drawing on the UK Biobank, the AMP-PD cohort, and the All of Us program, reported a similar increase in risk and even supplied functional evidence from a fruit fly model, showing that the protein encoded by ITSN1, called Intersectin-1, interacts with alpha-synuclein, the sticky protein that clumps in the brains of Parkinson’s patients. What remained unclear was whether patients carrying these variants show a recognizable clinical signature.

To answer that question, the ROPAD team turned to their own trove of data. They analyzed 8,660 reportedly unrelated Parkinson’s disease patients recruited between April 2019 and August 2024, drawn from Europe (68 percent), North America (16 percent), Israel (10 percent), Turkey (4 percent), and South America (2 percent). Crucially, all of these patients had undergone exome or genome sequencing and had no relevant variants in known Parkinson’s genes. That exclusion criterion matters: the researchers removed anyone carrying a pathogenic or likely pathogenic variant in dominant Parkinson’s genes such as LRRK2, SNCA, VPS35, RAB32, or CHCHD2, anyone with two heterozygous or one homozygous pathogenic variant in recessive genes including PARK7, PINK1, and PRKN, and anyone with a pathogenic or risk-factor variant in GBA1, the most common genetic contributor to the disease. By stripping out known genetic explanations, the team could ask whether ITSN1 variants stand on their own as a risk factor.

As a comparison group, the researchers examined 210,657 exome- or genome-sequenced individuals from the CENTOGENE Biodatabank, people referred for routine diagnostic testing, healthy parents in trio analyses, or participants in other observational studies, none of whom had been referred for or diagnosed with Parkinson’s disease. Loss-of-function variants were defined rigorously as start-loss, stop-gain, stop-loss, splice-donor, splice-acceptor, or frameshift changes, identified through a validated in-house bioinformatic pipeline. The team then mined electronic case report forms for clinical details, including year of birth, sex, age at disease onset, age at diagnosis, age at enrollment, family history, and motor scores from a partial Unified Parkinson’s Disease Rating Scale examination.

The result was striking. Thirteen of the 8,660 patients, or 0.15 percent, carried heterozygous loss-of-function variants in ITSN1, compared with just 0.025 percent of the 210,657 comparison individuals. That difference translates into an odds ratio of 6.09, with a 95 percent confidence interval of 3.31 to 11.19 and a p-value of 1.34 times ten to the minus six, a level of statistical significance that is difficult to dismiss. The allele-level comparison tells the same story: the proportion of ITSN1 loss-of-function alleles in the Parkinson’s patients, 0.075 percent, is roughly six times higher than the proportion found in non-Finnish European individuals in the Genome Aggregation Database, the reference catalog that population geneticists use as a baseline for how common variants should be. The enrichment held against every other population in that database as well.

Perhaps most convincing is how neatly these numbers overlap with the earlier studies. The confidence interval from the ROPAD analysis largely overlaps those reported in the two prior association studies, which found odds ratios of 7.3 and 10.5 respectively. The carrier frequency of 0.15 percent in ROPAD matches the 0.15 percent reported in the deCODE-led meta-analysis and the 0.14 percent in the family study. Within the ROPAD cohort itself, ITSN1 loss-of-function variants rank as the sixth most common disease-relevant genetic finding, trailing only variants in GBA1, LRRK2, PRKN, SNCA, and GCH1. For a gene that was essentially invisible to Parkinson’s researchers a few years ago, that is a rapid ascent.

Digging into the variants themselves, the team identified 12 distinct ITSN1 loss-of-function changes among the 13 patients: four nonsense mutations, six frameshift variants, and two splice site changes. Eleven of the twelve appeared only once, and one, a small deletion designated c.2842_2843del, was found in two patients. When the researchers tested whether those two German patients were related, analysis of extended haplotypes found no evidence of close relatedness or a shared founder chromosome, suggesting the variant arose independently in each case. This pattern of largely private, one-off mutations contrasts sharply with the genetics of other dominant Parkinson’s genes, where a handful of recurrent variants, such as the famous LRRK2 G2019S change, account for most cases. It also hints that the mutational spectrum of ITSN1 resembles that of genes where virtually any disruption of the protein is harmful.

There is an intriguing twist. More than 40 distinct ITSN1 loss-of-function variants have already been reported in individuals with autism and neurodevelopmental disorders, and four of the variants found in the ROPAD patients had appeared in that literature. This overlap raises the possibility of pleiotropy, the phenomenon in which a single gene produces different outcomes depending on context. Intersectin-1 is a scaffolding protein involved in clathrin-mediated endocytosis, synaptic vesicle recycling, and actin and CDC42-related signaling, processes essential both for building neural circuits during development and for maintaining them across a lifetime. Losing one functional copy, a state called haploinsufficiency, might disturb neurodevelopmental circuitry in childhood or undermine neuronal maintenance later in life. Which outcome prevails may depend on genetic modifiers, the residual expression produced by splice-altering variants, environmental stressors, and other factors scientists have yet to untangle.

On the clinical side, the ROPAD analysis found that patients carrying ITSN1 variants look, in most respects, like ordinary Parkinson’s patients. The male-to-female ratio, the proportion with a positive family history, the age at diagnosis, the age at enrollment, and the disease duration all failed to differ significantly between carriers and non-carriers. A multiple linear regression of motor scores adjusted for disease duration also found no significant difference, though the p-value of 0.075 leaves open the possibility of a subtle effect. Interestingly, the two earlier large-cohort studies did report significantly younger ages at onset among carriers, with mean or median onsets in the early sixties versus around seventy in non-carriers. The ROPAD cohort as a whole skews young, with a mean and median onset of 55 years, which likely explains why the same signal did not emerge here. Notably, the median onset of 53 years among ROPAD carriers is comparable to the 47-year average onset in the five family-study patients, and one ROPAD participant carried both an ITSN1 deletion and a mild GBA1 variant, a combination the researchers excluded from their main analysis because the GBA1 change may have modified her disease risk, echoing what has been documented in people carrying both LRRK2 and GBA1 variants.

Taken together, the findings cement ITSN1 as a genuine Parkinson’s disease gene, one that produces a form of the illness clinically indistinguishable from idiopathic disease. The authors propose the designation PARK-ITSN1 for this genetic entity and call for further research into its natural history and treatment responses, questions that will matter as genetic testing becomes routine and as pharmaceutical companies design trials stratified by genotype. The study also carries a broader lesson about the power of deeply curated clinical and genetic datasets: when a diagnostic laboratory pairs sequencing with systematic phenotyping across thousands of patients, even vanishingly rare risk factors, present in fewer than two people per thousand, can be detected, validated, and connected to the biology of one of the world’s most common neurodegenerative diseases.

Subject of Research: Association between ITSN1 loss-of-function variants and Parkinson's disease risk in the ROPAD cohort

Article Title: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease

Article References: Ganoza, C. A., Westenberger, A., Paul, J. J., Curado, F., Somerville, E. N., Rennecke, J., Bauer, P., & Beetz, C. (2026). Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease. npj Parkinson's Disease, 12(1), Article 237. https://doi.org/10.1038/s41531-026-01562-x

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01562-x

Keywords: Parkinson's disease, ITSN1, genetics, loss-of-function variants, ROPAD study, haploinsufficiency, Intersectin-1, neurodegeneration, exome sequencing, age at onset, GBA1, pleiotropy

The research team, led by Xu Yang and Li-Min Xin of Beijing Huilongguan Hospital at Capital Medical University, together with senior author Tian-Mei Si of Peking University Sixth Hospital, recruited participants from a Chinese multicenter cohort known as ODMPIM — Objective Diagnostic Markers and Personalized Intervention in MDD Patients. The trial was registered on ClinicalTrials.gov as NCT02023567 in December 2013, and the study drew on nine psychiatric and general hospitals across China, from Peking University Sixth Hospital and Beijing Anding Hospital to sites in Tianjin, Shanxi, Hebei, Dalian and Shanxi Medical University. Ethics committees at every participating institution approved the protocol, and all participants gave written informed consent under the Declaration of Helsinki.

What makes the design unusually clean is the drug-naïve, first-episode restriction. Most studies of cognition in depression examine patients who have already been exposed to antidepressants, sometimes for years, which makes it difficult to separate the effects of the illness itself from the effects of treatment, chronicity or prior episodes. By enrolling only people who had never received psychotropic medication and were experiencing their first depressive episode, the researchers could ask a purer question: what does depression, in its untreated first appearance, actually do to the thinking brain — and does the answer depend on when in life the disorder first emerged?

The cutoff chosen was 30 years of age at onset. Patients whose depression first appeared before 30 were classified as younger-onset; those whose illness began at 30 or later were classified as older-onset. All patients completed the 17-item Hamilton Depression Rating Scale to quantify depressive severity, the Mini-International Neuropsychiatric Interview to confirm diagnosis, and the Childhood Trauma Questionnaire-Short Form to capture early adversity across emotional, physical and sexual abuse and neglect domains. Healthy controls completed the trauma questionnaire and the same cognitive battery, allowing the team to benchmark both patient subgroups against people without the disorder.

The cognitive assessment spanned five domains, each tapped by established neuropsychological instruments. Processing speed was measured with the Digit Symbol Coding Test and the Color Trial Test. Executive function was probed through the Stroop Color-Word Test and Auditory Verbal Fluency. Attention was assessed with the Continuous Performance Test-Identical Pairs, a demanding task requiring sustained vigilance to fleeting stimulus matches. Verbal learning and memory relied on the Hopkins Verbal Learning Test-Revised, while visual learning and memory used the Brief Visual Memory Test-Revised. Statistical analysis proceeded through multivariate analysis of covariance, followed by correlation and multiple linear regression models that asked which clinical variables best predicted cognitive performance.

The headline result is a stark asymmetry. Younger-onset patients showed impairments across all five cognitive domains relative to healthy controls — processing speed, attention, executive function, verbal learning and visual learning were all affected. Older-onset patients, by contrast, displayed a narrower profile, with deficits confined to processing speed, verbal learning and executive function, while their attention and visual memory performance did not differ significantly from the healthy comparison group. When the two patient subgroups were compared directly, the younger-onset group performed worse than the older-onset group specifically in processing speed and in learning on the Hopkins Verbal Learning Test-Revised, pointing to speed of mental processing and the capacity to acquire new verbal material as the domains most sensitive to early illness onset.

Equally revealing were the results that failed to materialize. Both patient subgroups reported significantly higher levels of childhood trauma than healthy controls, yet the rates of current suicidal ideation — assessed with the Mini-International Neuropsychiatric Interview — were similar between the younger- and older-onset groups. And in the regression models, neither total childhood trauma scores nor Hamilton depression severity predicted cognitive performance. This dissociation matters: it suggests that the cognitive differences between onset groups are not simply a byproduct of more severe depression or a heavier load of early adversity, but may reflect something intrinsic to the developmental timing of the disorder itself.

The regression analyses did surface other predictors. Younger age-at-onset and male sex both predicted poorer processing speed and weaker executive function, reinforcing the picture that an early-arriving illness, particularly in men, is associated with the most pronounced slowing and the greatest difficulty in flexible, goal-directed thinking. In a counterintuitive twist, the presence of suicidal ideation was associated with better processing speed. The authors frame the study as exploratory, and this association in particular invites cautious interpretation — but it hints that the cognitive signatures of depression may not map neatly onto clinical risk in straightforward ways, and that faster processing in some patients may coexist with acute psychological distress.

Why might an earlier onset leave a wider cognitive footprint? The authors’ framing points toward neurodevelopment. Cognitive abilities such as processing speed and verbal learning continue to mature through the third decade of life, and an illness that disrupts brain function during or before this window may interfere with abilities that are still consolidating, or may mark a more neurodevelopmentally rooted form of depression. A later onset, arriving after cognitive systems have fully matured, may spare some domains — attention and visual memory in this dataset — while still eroding speed, verbal learning and executive control. Age-at-onset, in other words, may act as a clinically relevant marker of cognitive heterogeneity, a way of subtyping major depressive disorder that carries direct implications for rehabilitation, occupational counseling and the monitoring of functional recovery in newly diagnosed adults.

The study’s limitations temper but do not erase its significance. The cross-sectional design captures a single moment in time and cannot establish whether early-onset patients will remain more impaired over the course of illness or treatment. The 30-year cutoff, while clinically meaningful, is ultimately a convention, and the authors describe their cognitive patterns as exploratory rather than definitive. Still, the scale of the cohort, the rigor of the five-domain battery and, above all, the drug-naïve first-episode design give the findings unusual weight. For a disorder diagnosed in hundreds of millions of people worldwide, the message is concrete: when a young adult walks into a clinic with a first episode of depression, the age at which the illness began may be one of the most informative numbers on the chart — a signal of how widely cognition has been affected, and of which patients deserve the closest attention to the thinking skills that underpin work, study and daily life.

Subject of Research: Age-at-onset differences in neurocognition, childhood trauma and suicidal ideation in drug-naïve first-episode major depressive disorder

Article Title: Neurocognition, childhood trauma and suicidal ideation in drug-naïve first-episode major depressive disorder: a comparison of younger- versus older-onset patients

Article References: Yang, X., Xin, L.-M., Fan, H.-Z., Lin, J.-Y., Yan, F., Yu, X., Su, Y.-A., & Si, T.-M. (2026). Neurocognition, childhood trauma and suicidal ideation in drug-naïve first-episode major depressive disorder: a comparison of younger- versus older-onset patients. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08695-6

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08695-6

Keywords: major depressive disorder, age-at-onset, neurocognition, childhood trauma, suicidal ideation, drug-naïve, first-episode, processing speed, executive function, verbal learning, BMC Psychiatry, multicenter cohort